摘要
【目的】探讨不同剂量沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭(CHF)患者的临床疗效。【方法】选择2019年1月至2022年1月延安大学附属医院收治的100例高血压合并CHF患者,按照随机数字表法将其分为大剂量组(常规治疗+沙库巴曲缬沙坦片100 mg)和小剂量组(常规治疗+沙库巴曲缬沙坦片50 mg),每组50例。比较两组疗效及治疗前后高敏C反应蛋白(hs-CRP)、内皮素-1(ET-1)、N-末端脑钠肽前体(NT-proBNP)水平,心功能指标以及用药后不良反应。【结果】大剂量组总有效率为90.00%(45/50),显著高于小剂量组的72.00%(36/50),差异有统计学意义(P<0.05)。治疗后,两组血清hs-CRP、ET-1水平均低于治疗前,且大剂量组低于小剂量组,差异有统计学意义(P<0.05);两组LVEDD、NT-proBNP均低于治疗前,LVEF高于治疗前,大剂量组各指标优于小剂量组,差异有统计学意义(P<0.05)。大剂量组不良反应发生率为20.00%(10/50),与小剂量组的10.00%(5/50)比较,差异无统计学意义(P>0.05)。【结论】大剂量沙库巴曲缬沙坦治疗高血压合并CHF疗效显著,可降低炎症因子水平,改善患者心功能,安全性好。
【Objective】To investigate the clinical efficacy of different doses of Sakubatroxvalsartan in the treatment of hypertensive patients with CHF.【Methods】From January 2019 to January 2022,100 patients with hypertension and CHF admitted to the Affiliated Hospital of Yan'an University were randomly divided into a large dose group(conventional treatment+Sakubatroxvalsartan tablets 100 mg)and a small dose group(conventional treatment+Sakubatroxvalsartan tablets 50 mg)according to the random number table.Two groups were compared in terms of efficacy,serum levels of high sensitivity C-reactive protein(hs-CRP),endothelin-1(ET-1),N-terminal-proBNP,cardiac function indicators,and adverse reactions after treatment.【Results】The total effective rate of the high-dose group was 90.00%(45/50),significantly higher than the 72.00%(36/50)of the low-dose group,with a statistically significant difference(P<0.05).After treatment,the serum levels of hs-CRP and ET-1 in both groups were lower than those before treatment,and the high-dose group was lower than the low-dose group,with a statistically significant difference(P<0.05);LVEDD and NT-proBNP in both groups were lower than those before treatment,while LVEF was higher than treatment;The indicators of the high-dose group were better than those of the low-dose group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 20.00%(10/50)in the high-dose group and 10.00%(5/50)in the low-dose group,with no statistically significant difference(P>0.05).【Conclusion】High dose Sakubatroxvalsartan is effective in the treatment of hypertension with CHF.It can reduce the level of inflammatory factors,improve the heart function of patients,and has good safety.
作者
董旺黎
雷杰喻
师文涛
DONG Wang-li;LEI Jie-yu;SHI Wen-tao(Shaanxi Kangfu Hospital,Xi'an Shaanxi 710065)
出处
《医学临床研究》
CAS
2023年第7期976-978,983,共4页
Journal of Clinical Research
